Skip to main content

Advertisement

SpringerLink
Log in

Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The anti-epileptic diphenylhydantoin (DPH; Dilantin®) selectively enhances the in vitro cytotoxicity of vinca microtubule poisons in both parent sensitive and multi-drug resistant (MDR) human tumor cells. The in vivo clinical activity of this combination has not been fully evaluated. Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicities, and preliminary antitumor activity of the combination of intravenous (IV) bolus vinorelbine (VRL) and oral diphenylhydantoin (DPH) in patients (pts) with refractory solid tumors. Methods: Cohorts of 3–6 pts with refractory cancer were treated with escalating doses of weekly IV bolus VRL (I –20.0 mg/m2; II –22.5 mg/m2; III –25.0 mg/m2; IV –27.5 mg/m2; V –30.0 mg/m2; VI –32.5 mg/m2) combined with a fixed oral dose of DPH (400 mg/day) until MTD or progression. During each 35 day cycle, pts received DPH 400 mg/day administered orally on Days −6 to Day +22 and weekly IV bolus infusion of VRL on Days +1, +8, +15, and +22. The cohort treated at the MTD was expanded to further define toxicity. Results: A total of 25 evaluable pts. (9 men; 16 women) were treated with VRL and DPH at dose levels I (n = 5), II (n = 3), III (n = 2), IV (n = 3), V (n = 7) and VI (n = 5) in 5 week cycles over a 16 month period. Dose limiting toxicity occurred at dose level VI (VRL 32.5 mg/m2) and included grade 3 leukopenia (n = 2), grade 3 neutropenia (n = 1) and grade 4 neutropenia (n = 1) occurring within the first cycle of treatment. There were no responses, however 9 pts had stable disease of variable duration (8–56 weeks) and received a median of 2 cycles of treatment (range 2–14). Conclusion: Intravenous bolus administration of VRL and oral administration of a fixed dose of DPH was well tolerated according to the schedule reported here. Although there were no responses, several patients had prolonged disease stabilization. The recommended phase II dose of VRL when used in this combination is 30 mg/m2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Tellingen O, Sips JHM, Beijnen JH, Bult A, Nooijen WJ: Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives. Anticancer Res 12: 1699–1716, 1992

    CAS  PubMed  Google Scholar 

  2. Edincott JA, Ling V: The biochemistry of P. gylcoprotein mediated multidrug resistance. Ann Rev Biochem 58: 137–171, 1989

    Article  PubMed  Google Scholar 

  3. Rowinsky EK, Donehower RC: The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Thera 52: 35–84, 1991

    Article  CAS  Google Scholar 

  4. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharm Rev 42: 155–199, 1990

    CAS  PubMed  Google Scholar 

  5. Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport and cell death. J Clin Oncol 17: 1061–1070, 1999

    CAS  PubMed  Google Scholar 

  6. Cros S, Potier P: La Nor-anhydrovinblastine (Navelbine) Nouveau type de compose antitumoral du groupe de la vinblastine. Collogue de Marrakech (Maroc): 16–20, 1985

  7. Mangeney P, Andriamialisoa RZ, Langlois Y: A new class of antitumor compounds: 5′-nor and 5′,6′-seco derivatives of vinblastine type alkaloids. Journal of Organic Chemistry 44: 3765–3771, 1979

    Article  CAS  Google Scholar 

  8. Potier P: The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16(2 Suppl 4): 2–4, 1989

    CAS  Google Scholar 

  9. Binet S, Fellous A, Meininger V: In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16(Suppl 4): 5–8, 1989

    CAS  PubMed  Google Scholar 

  10. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP, Meininger V: Biochemical effects of Navelbine on tubulin associated proteins. Semin Oncol 16(Suppl 4): 9–14, 1989

    CAS  Google Scholar 

  11. Himes RH, Kersey RN, Hellier-Bettinger I, Samson FE: Action of vinca alkaloids vincristine, vinblastine and desacetylvinblastine amide on microtubules in vitro. Cancer Res 36: 3798–3801, 1976

    CAS  PubMed  Google Scholar 

  12. Cvitkovic E, Izzo J: The current and future place of vinorelbine in cancer therapy. Drugs 44(Suppl 4): 36–45, 1992

    Google Scholar 

  13. Hohneker JA: A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 21(Suppl 10): 42–60, 1994

    CAS  Google Scholar 

  14. Canobbio L, Boccardo F, Guarneri D, Calabria C, Decensi A, Curotto A, Martorana G, Giuliani L: Phase II study of Navelbine in advanced renal cell carcinoma. Eur J Cancer 27(6): 804–805, 1991

    CAS  Google Scholar 

  15. Mahjoubi M, Kattan J, Droz J, Philippot I, Pautier P, Boutan-Laroze A, Azub M, Theodore C: Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer. Eur J Cancer 29A(2): 285–286, 1993

    CAS  PubMed  Google Scholar 

  16. Bruni GS, Posca T, Celiento G: Gemcitabine and navelbine in elderly patients with bladder cancer: pilot study (Abstract). Proc Eur Soc Med Oncol 23: 307a, 1998

    Google Scholar 

  17. Sobecks RM, Stadler WM, Daugherty CK, Ratain MJ, Voglezang NJ: Vinorelbine and paclitaxel in relapsed metastatic bladder carcinoma (Abstract). Proc Am Soc Clin Oncol 16: 344a, 1997

    Google Scholar 

  18. Le Cesne A, Droz JP, Kattan J: Phase II trial of a combination of ifosfamide, Navelbine, and epirubicin as salvage chemotherapy in refractory germ cell tumors (Abstract). Proc Am Soc Clin Oncol 10: 174a, 1991

    Google Scholar 

  19. Bokemeyer C, Droz JP, Hanauske A: Treatment of relapsed non-seminomatous germ-cell tumors with vinorelbine-a trial of the phase I-II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 16(1): 29–31, 1993

    Google Scholar 

  20. Van Zuylen L, Nooter K, Sparreboom A, Verweij J: Development of multidrug-resistance convertors: Sense or nonsense? Invest New Drugs 18: 205–220, 2000

    CAS  PubMed  Google Scholar 

  21. Ganapathi R, Hercbergs A, Grabowski D, Ford J: Selective enhancement of vincristine cytotoxicity in multidrug resistant tumor cells by Dilantin (phenytoin). Cancer Res 53: 3262–3265, 1993

    CAS  PubMed  Google Scholar 

  22. Kawamura KI, Grabowski D, Weizer K, Bukowski R, Ganapathi R: Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Br J Cancer 73(2): 183–188, 1996

    CAS  PubMed  Google Scholar 

  23. Peereboom DM, Ganapathi R, Van Tellingen O, Grabowski D, Olencki T, Budd GT, Wood L, McLain DA, Bukowski RM: Phase I trial of vinblastine plus phenytoin: Pharmacokinetic analysis (Abstract). Proc Annu Meet Am Assoc Cancer Res 37: A1243, 1996

    Google Scholar 

  24. Perry MC: Appendix: WHO toxicity guidelines. In: Perry MC (ed) The Chemotherapy Source Book. Baltimore, MD, Williams and Wilkins; 1992, pp. 1132–1144

    Google Scholar 

  25. Kornblith PL, Callahan LV, Caswell PA: Growth-inhibitory effects of dipenhnylhydantoin of human brain tumor cells in culture. Neurosurgery 2: 122–127, 1978

    CAS  PubMed  Google Scholar 

  26. Estus S, Blumer JL: Role of microtubule assembly in phentyotin teratgenic action in the sea urchin (Arabica puntulata) embryo. Mol Pharmacol 36: 708–715, 1989

    CAS  PubMed  Google Scholar 

  27. Goa KL, Faulds D: Focus on vinorelbine. Drugs and Aging 5(3): 201–202, 1994

    Google Scholar 

  28. Furuse K, Niitani H, Wakui A: Phase I study on vinorelbine by single or intermittent administration (Abstract). Invest New Drugs 7: 456, 1989

    Google Scholar 

  29. Berthaud P, Le Chavalier T, Ruffle P, Baldoyrou P, Arriagada R, Bosson F, Tursz T: Phase I–II study of vinorelbine plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 28A: 1863–1865, 1992

    CAS  PubMed  Google Scholar 

  30. Jassem J, Karnicka-Mlodkowska, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzonia A, Gozzelino F, Planting A, van Zandwijk N: Phase II study of vinorelbine in previously treated small cell lung cancer patients. Eur J Cancer 29A(12): 1720–1722, 1993

    CAS  PubMed  Google Scholar 

  31. Gasparini G, Caffo O, Barni S, Frontini C, Testolin A, Guglielmi RB, Ambrosini G: Vinorelbine, is an active antiproliferative agent in pretreated advanced breast cancer patients: A Phase II study. J Clin Oncol 12: 2094–2101, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation;, USA

    Thomas E. Hutson, Ram Ganapathi, Paul Elson, Tarek Mekhail, Thomas Olencki, G. Thomas Budd & Ronald M. Bukowski

  2. Clinical Pharmacology Laboratory, Taussig Cancer Center, Cleveland Clinic Foundation;, USA

    Thomas E. Hutson, Ram Ganapathi, Tarek Mekhail & Ronald M. Bukowski

  3. Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, USA

    Thomas E. Hutson, Ram Ganapathi, Tarek Mekhail, Thomas Olencki, G. Thomas Budd & Ronald M. Bukowski

Authors
  1. Thomas E. Hutson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ram Ganapathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Elson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tarek Mekhail
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Olencki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Thomas Budd
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ronald M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hutson, T.E., Ganapathi, R., Elson, P. et al. Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma. Invest New Drugs 22, 277–284 (2004). https://doi.org/10.1023/B:DRUG.0000026253.02502.ce

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000026253.02502.ce

Search

Navigation